OncoMed Pharmaceuticals Company Profile (NASDAQ:OMED)

OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) issued its earnings results on Monday, May, 8th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.62) by $0.01. The firm earned $6.20 million during the quarter, compared to the consensus estimate of $5.85 million. The firm's revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.90) EPS. View OncoMed Pharmaceuticals' Earnings History.

8 brokers have issued 12 month price targets for OncoMed Pharmaceuticals' shares. Their predictions range from $5.00 to $16.00. On average, they anticipate OncoMed Pharmaceuticals' share price to reach $7.71 in the next year. View Analyst Ratings for OncoMed Pharmaceuticals.

Here are some recent quotes from research analysts about OncoMed Pharmaceuticals stock:

• 1. Cantor Fitzgerald analysts commented, "Restructuring plan should lengthen cash runway by at least a year, and we view a focus on assets with potential milestone opportunities as a positive given." (4/25/2017)
• 2. According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (4/13/2017)
• 3. HC Wainwright analysts commented, "We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak wrote in a note.Related Link: Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial FailMeanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017."We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite the compound failed in pancreatic cancer trial."In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with long-term benefits and free-up OncoMed's resources to pursue new development activities," (9/22/2016)

OncoMed Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,510,923 shares, a decline of 40.4% from the June 15th total of 2,535,442 shares. Based on an average daily trading volume, of 492,187 shares, the days-to-cover ratio is presently 3.1 days. Approximately 6.8% of the shares of the company are short sold.

Some companies that are related to OncoMed Pharmaceuticals include Advaxis (ADXS), Codexis (CDXS), Corvus Pharmaceuticals (CRVS), Voyager Therapeutics (VYGR), Organovo Holdings (ONVO), Zynerba Pharmaceuticals (ZYNE), Horizon Discovery Group PLC (HZD), Protagonist Therapeutics (PTGX), NewLink Genetics Corporation (NLNK), Arbutus Biopharma Corporation (ABUS), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Novelion Therapeutics (NVLN), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), Genocea Biosciences (GNCA), Chromadex Corp (CDXC) and Pluristem Therapeutics (PSTI).

OncoMed Pharmaceuticals' management team includes the folowing people:

• Paul J. Hastings, Chairman of the Board, President, Chief Executive Officer
• Sunil Patel, Chief Financial Officer, Senior Vice President - Corporate Development and Finance
• John A. Lewicki Ph.D., Executive Vice President, Chief Scientific Officer
• Austin Gurney Ph.D., Senior Vice President, Molecular and Cellular Biology
• Tim Hoey Ph.D., Senior Vice President, Cancer Biology
• Alicia J Hager J.D. Ph.D., Vice President, General Counsel
• Jack W. Lasersohn J.D., Lead Independent Director
• Perry A. Karsen, Director
• Rick E. Winningham, Director
• Elisha P. Gould III, Independent Director

Shares of OncoMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OncoMed Pharmaceuticals stock can currently be purchased for approximately $3.62.